Skip to content

PharmaLex Strengthens Global Reach and Local Support with Offices in China

By asianet

PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced the opening of a new branch in Beijing, China, giving global clients access to a team of regulatory experts in the region. As of September 2022, the newly established PharmaLex Beijing team, which includes personnel joining from … Continued

Global Wellness Leader, iHerb Celebrates Its 26th Anniversary of Making Health & Wellness Products Easy and Affordable

By asianet

— The world’s largest eCommerce platform, dedicated to vitamins, minerals, and supplements marks another year of continued expansion with special promotions iHerb, the destination for a curated selection of the world’s best health and wellness products, is proud to commemorate its 26th anniversary. Founded in 1996 on the belief that a healthy and balanced life … Continued

Cambrex Completes First Phase of $30 Million Capacity Expansion Project in High Point, North Carolina

By asianet

Cambrex today announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina. The newly constructed space adds analytical and chemical development laboratories totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These … Continued

Top healthcare executive sets up fundraising platform matching healthcare startups to medical investors

By asianet

– Chris Lee aims to transform healthcare fundraising through VentureBlick’s fundraising platform and professional community Chris Lee, one of the most experienced healthcare executives having held senior positions including president of Medtronic Asia Pacific and head of Bayer Healthcare Asia Pacific, today announced his new role as the founder and CEO of VentureBlick, a platform … Continued

PFIZER RANKED LEADING COMPANY IN ASIA FOR COVID-19 RESPONSE AND PATIENT-CENTRIC APPROACH BY ASIAN PATIENT GROUPS

By asianet

– Pfizer is ranked 1st in Australia/New Zealand region and overall 2nd in Asia in its corporate reputation from a patient perspective – Asian patient groups have placed the pharma industry 1st for corporate reputation in Asia amongst other healthcare sectors Pfizer has been ranked first in its Covid-19 response, patient centricity, patient safety and … Continued

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

By asianet

The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval. “We are very excited to finally have … Continued

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome(R) technology platform in nutraceuticals

By asianet

Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion’s Dispersome(R) technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the … Continued

Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases

By asianet

— Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company’s development of ocular tissue rejuvenation therapeutics Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic … Continued

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

By asianet

– Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union – Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the … Continued